Innate Pharma: Moving Into The Padcev Space

2025-03-21 09:10:35 ET

Summary

• Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025.
• Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential.
• Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requiring equity raises or partnerships, in my opinion.
• Despite risks, including potential dilution and high development costs, I remain optimistic and maintain a "Buy" rating for IPHA.

Topline Summary and Update

Read the full article on Seeking Alpha

For further details see: